MERCK, SANDOZ PRESS RELEASES ON BRISTOL CARE STUDY DRAW SCRUTINY FROM FDA AD DIVISION; RPR TAXOTERE NEWS RELEASES DEEMED "NOT OBJECTIVE" BY AGENCY
Executive Summary
Merck and Sandoz have been cited by FDA's Division of Drug Marketing, Advertising & Communications for issuing press releases attempting to piggyback on clinical trial results for Bristol-Myers Squibb's Pravachol.